Wall Street is positive on Vyne Therapeutics Inc (VYNE). On average, analysts give VYNE a Strong Buy rating. The average price target is $6.312, which means analysts expect the stock to increase by 164.10% over the next twelve months.
That average ranking earns VYNE an Analyst Rating of 79, which is better than 79% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Vyne Therapeutics Inc Stock Today?
Vyne Therapeutics Inc (VYNE) stock is trading at $2.39 as of 11:35 AM on Wednesday, Jan 27, a decline of -$0.11, or -4.4% from the previous closing price of $2.50. The stock has traded between $2.33 and $2.47 so far today. Volume today is elevated. So far 8,786,219 shares have traded compared to average volume of 6,262,340 shares.